Vimarsana
Biggest News Aggregation in the World

Page 20 - Compugen Ltd News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Compugen Ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Compugen Ltd Today - Breaking & Trending Today

Israel stocks slip on SVB failure, government vows aid for tech firms - Vimarsana News

Israel stocks slip on SVB failure, government vows aid for tech firms

Israel's tech sector is the country's main growth engine and its relationship with the Silicon Valley region is strong. Many Israeli startups had accounts at SVB although the amounts are unconfirmed.

Source: jpost.com
Israel stocks slip on SVB failure, government vows aid for tech firms - Vimarsana News

Israel stocks slip on SVB failure, government vows aid for tech firms

By Steven Scheer JERUSALEM (Reuters) - Israeli bank and insurance company shares were more than 2.5% lower on the Tel Aviv Stock Exchange (TASE) on Su...

Source: wsau.com
Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference - Vimarsana News

Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

/PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...

Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference - Vimarsana News

Compugen to Participate in a Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

HOLON, ISRAEL, March 8, 2023 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in a f...

Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study - Vimarsana News

Compugen Doses First Patient in Triple Combination COM701, COM902 and Pembrolizumab MSS CRC Proof-of-Concept Study

Study builds on clinical benefit reported in heavily pretreated MSS CRC patients with liver metastases treated with dual combination of COM701 and nivolumab Initial findings